StreetAlpha.app
Home › Stocks › DNLI

Denali Therapeutics Inc. (DNLI)

Healthcare
$18.00
▼ −0.44%
LAST CLOSE · NOV 17

Denali develops biological medicines that can reach the brain, mainly for neurodegenerative and rare lysosomal storage diseases. It last closed at $18.00 on Nov 17, down 0.44% on the day. The average 12-month price target from 4 analysts is $32.75 (+81.9% from the last close), with a high of $37.00 and a low of $24.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $435K, the largest $435K.

AI Auto Pilots
Is DNLI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$21.4M
Net income
−$314.4M
−1470.5% margin
EPS (diluted)
−$1.72
Free cash flow
−$450.0M
−2104.5% margin
Valuation
Market cap
$2.9B
160.3M shares
P/E
–
No P/E while losing money
Price to sales
134.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$102.9M
At Sep 30
Shareholder equity
$926.4M
Shares outstanding
160.3M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $48.7M$48.7MFY2021FY2022: $105.1M$105.1MFY2022FY2023: $330.5M$330.5MFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From DNLI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on DNLI in the past 90 days
Average 12-month target
$32.75
▲ 81.9% upside

Based on 4 analysts who set a price target on DNLI in the past 90 days. The average target is $32.75, with a high of $37.00 and a low of $24.00, compared with the last close of $18.00.

Low $24.00Avg $32.75High $37.00
Blue marker: last close $18.00
Highest target$37.00
Average target$32.75
Lowest target$24.00
Latest rating changes
Morgan StanleyTarget raised
Nov 13Buy$36 → $37
Wells FargoInitiated
Nov 13Buy$35
WedbushMaintained
Nov 4Buy$24
B. Riley SecuritiesMaintained
Aug 25Buy$35
UBSMaintained
Aug 7Buy$34
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget raisedBuy$36 → $37
Nov 13Wells FargoInitiatedBuy$35
Nov 4WedbushMaintainedBuy$24
Aug 25B. Riley SecuritiesMaintainedBuy$35
Aug 7UBSMaintainedBuy$34
Loading…

Technical Analysis

DNLI · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 9% below its 50 day average. It is 18% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $17.81, and the nearest resistance the Pivot R1 at $18.45.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 4.9%/day
Key levels
$27.3052 week high+51.7%
$21.98100 day average+22.1%
$21.18200 day average+17.7%
$19.6150 day average+8.9%
$19.35Swing high (Oct 20)+7.5%
$19.1920 day average+6.6%
$18.45Pivot R1+2.5%
$18.00Last close
$17.81Pivot−1.1%
$17.36Pivot S1−3.6%
$17.33Swing low (Oct 19)−3.7%
$15.3452 week low−14.8%
Indicators
RSI (14)38.68Weak, oversold below 30Neutral
MACD-0.26Below its signal lineBearish
Stochastic9.1Near the bottom of its rangeOversold
ADX (14)21.1Weak trend
Williams %R-83.5Oversold below −80, overbought above −20Oversold
CCI (20)-147.2Oversold below −100, overbought above 100Oversold
Rate of change−7.5%Change over 10 sessionsBearish
ATR (14)$0.88Typical daily range, 4.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DNLI

What happened before

See how DNLI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DNLI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DNLI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DNLI in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$435K
Largest print
$435K
Loading…

DNLI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●133 buying vs 129 selling
  • ▼Held by funds -2.4 pts
  • ▼Funds holding -8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding286294−2.7%
In funds' top 10550.0%
Held by funds95.1%97.5%−2.4 pts
New / increased35 / 9852 / 116−20.8%
Reduced / sold out88 / 4167 / 28+35.8%
Put/call ratio–0.05–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DNLI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNLI is in one of them and how their past DNLI trades turned out.

DNLI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DNLI in an article yet. Here's the latest on the wider market.

About Denali Therapeutics

Denali is a biotechnology company based in South San Francisco, California, that develops biological medicines for serious diseases. Its TransportVehicle technology is designed to carry large molecule drugs, such as enzymes and antibodies, past the barrier that normally keeps them out of the brain. The company focuses on neurodegenerative conditions and rare lysosomal storage disorders, and its medicines are aimed at patients and the doctors who treat them.

Headquarters
South San Francisco, CA